Diffuse SSc Complications — RACP Adult Medicine MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: E — Interstitial lung disease
Anti-Scl-70 (topoisomerase I) antibodies are associated with diffuse cutaneous systemic sclerosis and carry a high risk of interstitial lung disease (ILD), occurring in up to 80% of anti-Scl-70 positive patients. Annual HRCT and PFTs (including DLCO) are recommended for screening. Anti-centromere antibodies, in contrast, are associated with limited cutaneous SSc and carry higher risk of pulmonary arterial hypertension. Scleroderma renal crisis is associated with anti-RNA polymerase III antibodies.
Reference: eTG – 2025 – Rheumatology; EULAR – 2023 – SSc Screening Recommendations